ES2194640T3 - Solucion acuosa estable del derivado de la talidomida (em 12), para su administracion parenteral, y su procedimiento de preparacion. - Google Patents

Solucion acuosa estable del derivado de la talidomida (em 12), para su administracion parenteral, y su procedimiento de preparacion.

Info

Publication number
ES2194640T3
ES2194640T3 ES00104208T ES00104208T ES2194640T3 ES 2194640 T3 ES2194640 T3 ES 2194640T3 ES 00104208 T ES00104208 T ES 00104208T ES 00104208 T ES00104208 T ES 00104208T ES 2194640 T3 ES2194640 T3 ES 2194640T3
Authority
ES
Spain
Prior art keywords
parenteral administration
talidomide
derivative
water solution
preparation procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00104208T
Other languages
English (en)
Inventor
Tieno Dr Germann
Heinrich Kugelmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gruenenthal GmbH
Original Assignee
Gruenenthal GmbH
Chemie Gruenenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19914621A external-priority patent/DE19914621C2/de
Application filed by Gruenenthal GmbH, Chemie Gruenenthal GmbH filed Critical Gruenenthal GmbH
Application granted granted Critical
Publication of ES2194640T3 publication Critical patent/ES2194640T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Solución acuosa estable que contiene 3-(1-oxo-1, 3- dihidro-isoindol-2-il)-piperidín-2, 6-diona (EM 12) para administración parenteral, estando disuelta la EM 12 en solución de glucosa isotónica y siendo el valor pH de la solución menor o igual a 5, 5.
ES00104208T 1999-03-31 2000-03-01 Solucion acuosa estable del derivado de la talidomida (em 12), para su administracion parenteral, y su procedimiento de preparacion. Expired - Lifetime ES2194640T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19914621A DE19914621C2 (de) 1997-10-06 1999-03-31 Stabile wässrige Lösung von EM 12

Publications (1)

Publication Number Publication Date
ES2194640T3 true ES2194640T3 (es) 2003-12-01

Family

ID=7903088

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00104208T Expired - Lifetime ES2194640T3 (es) 1999-03-31 2000-03-01 Solucion acuosa estable del derivado de la talidomida (em 12), para su administracion parenteral, y su procedimiento de preparacion.

Country Status (25)

Country Link
US (1) US6306879B1 (es)
EP (1) EP1040838B1 (es)
JP (1) JP2000290180A (es)
KR (1) KR20010006930A (es)
CN (1) CN1270027A (es)
AR (1) AR023199A1 (es)
AT (1) ATE235256T1 (es)
AU (1) AU766250B2 (es)
BR (1) BR0001112A (es)
CA (1) CA2302886A1 (es)
CO (1) CO4970704A1 (es)
DE (1) DE50001522D1 (es)
DK (1) DK1040838T3 (es)
ES (1) ES2194640T3 (es)
HU (1) HUP0001312A2 (es)
IL (1) IL135340A0 (es)
NO (1) NO20001658L (es)
NZ (1) NZ503428A (es)
PE (1) PE20001597A1 (es)
PL (1) PL339336A1 (es)
PT (1) PT1040838E (es)
RU (1) RU2238727C2 (es)
SI (1) SI1040838T1 (es)
SK (1) SK4632000A3 (es)
ZA (1) ZA200001618B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7268148B2 (en) * 1999-05-20 2007-09-11 Regents Of The University Of Michigan Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
DE19957342A1 (de) * 1999-11-29 2001-05-31 Gruenenthal Gmbh Verfahren zur Behandlung und/oder Prophylaxe von IL-12-bedingten Erkrankungen
US7320991B2 (en) 2001-02-27 2008-01-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Analogs of thalidomide as potential angiogenesis inhibitors
US20030021816A1 (en) * 2001-06-06 2003-01-30 Sewon Kang Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
NZ531294A (en) * 2001-08-06 2005-11-25 Childrens Medical Center Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
US7973057B2 (en) 2003-09-17 2011-07-05 The United States Of America As Represented By The Department Of Health And Human Services Thalidomide analogs
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1509078A1 (ru) * 1979-07-30 1989-09-23 Бальнеоозокеритолечебница N1 Трускавецкого Территориального Совета По Управлению Курортами Профсоюзов Способ лечени пародонтоза
SU1595521A1 (ru) * 1987-08-07 1990-09-30 Киевский Медицинский Институт Им.Акад.А.А.Богомольца Способ лечени заболеваний пародонта слизистой оболочки полости рта
SU1768021A3 (ru) * 1991-03-04 1992-10-07 Л.М.Богатырчук и Л.В.Богатырчук Способ повышени компенсаторных возможностей организма
CA2104776C (en) * 1991-04-17 2003-12-09 Kurt Eger Thalidomide derivatives, method of manufacture and use thereof in medicaments
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
DE19743968C2 (de) * 1997-10-06 2002-07-11 Gruenenthal Gmbh Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen

Also Published As

Publication number Publication date
IL135340A0 (en) 2001-05-20
JP2000290180A (ja) 2000-10-17
NO20001658L (no) 2000-10-02
BR0001112A (pt) 2001-08-21
ATE235256T1 (de) 2003-04-15
PT1040838E (pt) 2003-08-29
CN1270027A (zh) 2000-10-18
KR20010006930A (ko) 2001-01-26
RU2238727C2 (ru) 2004-10-27
AR023199A1 (es) 2002-09-04
CO4970704A1 (es) 2000-11-07
EP1040838A1 (de) 2000-10-04
DK1040838T3 (da) 2003-05-26
SK4632000A3 (en) 2000-10-09
PL339336A1 (en) 2000-10-09
AU766250B2 (en) 2003-10-09
HUP0001312A2 (en) 2001-03-28
HU0001312D0 (en) 2000-06-28
NZ503428A (en) 2001-08-31
EP1040838B1 (de) 2003-03-26
HK1033645A1 (en) 2001-09-14
AU2420400A (en) 2000-10-05
PE20001597A1 (es) 2001-01-20
NO20001658D0 (no) 2000-03-30
DE50001522D1 (de) 2003-04-30
SI1040838T1 (en) 2003-08-31
CA2302886A1 (en) 2000-09-30
US6306879B1 (en) 2001-10-23
ZA200001618B (en) 2000-10-25

Similar Documents

Publication Publication Date Title
IS6166A (is) 5-sýanó-2-amínópýrimidín afleiður
ES2136103T3 (es) Procedimiento para la preparacion de derivados de estaurosporina.
TR200200579T2 (tr) Amino-tirazolpiridin türevleri.
NO992617L (no) Sulfinsyrederivater, deres fremstilling og anvendelse
TR200201072T2 (tr) 4-Triflorometilsulfinilpirazol türevi hazırlama süreci
UY26082A1 (es) Derivados de 1,4-diazabiciclo [3.2.2] nonan-4-carboxilato y -carboxamidas, su preparacion y su aplicacion en terapeutica
NO20022201L (no) Lösninger inneholdende Epinastin
HRP20021011B1 (en) Highly concentrated stable meloxicam solutions
GR1003658B (el) Δισκιο μητρας που καθιστα δυνατη την παρατεταμενη απελευθερωση της τριμεταζιδινης μετα χορηγηση δια της στοματικης οδου
ES2194640T3 (es) Solucion acuosa estable del derivado de la talidomida (em 12), para su administracion parenteral, y su procedimiento de preparacion.
ATE265846T1 (de) Butorphanol enthaltende formulierungen mit verzögerter freisetzung
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
EE200100066A (et) Naatriumkloriidi kasutamine kamptotetsiini derivaatide manustamisest tingitud gastrointestinaalsetekõrvaltoimete vähendamiseks
HRP20010885B1 (en) Ethanesulfonyl-piperidine derivatives
AR027349A1 (es) Derivados de amidas heterociclicas
ITMI20000293A0 (it) Derivati del 3,9-diazabiciclo [3.3.1]nonano ad attivita' analgesica
DK1140810T3 (da) Benzensulfonamidderivater samt deres anvendelse
YU3701A (sh) Supstituisani fenilamidini sa antitrombskim dejstvom
YU74401A (sh) Postupak za dobijanje 2s-3-amino-3-arilpropionske kiseline i njenih derivata
ATE222103T1 (de) Inklusionskomplexe in waessriger loesung
DE50002107D1 (de) Alpha-liponsäure(-derivate)enthaltende retardform
UA38504A (uk) Кардіопротекторний засіб для лікування гострого інфаркту міокарда, спосіб його отримання та спосіб його застосування
RU2000105080A (ru) Препарат для лечения гриппа
UA23996C2 (uk) Спосіб одержаhhя корвітиhу